InSilicoNext runs on a two-layer model: a core in-house team of PhD-qualified computational biologists who lead, manage, and quality-check every project—supported by a curated network of 75+ subject-matter experts who add specialist depth across every domain we cover. Your project is never handled by a generalist stretching into unfamiliar territory: the right specialist is matched to your exact data type, organism, and biological question, and every analysis is reviewed in-house before it reaches you.
The consistency of a permanent team combined with the specialist depth only a large, domain-specific expert network can provide.
Your project is always assigned a named core team lead who manages the analysis, communicates with you directly, coordinates any subject-matter-expert contributions, and owns the quality of the final deliverable from scoping to publication.
When a project needs highly specialised knowledge—a rare organism, an emerging assay type, or a niche statistical method—the core team draws on the right subject-matter expert from our network, without any loss of coordination or quality control.
Regardless of whether subject-matter experts contribute, all results are reviewed internally by a core team member before delivery. The same rigour applies to every project—not just those handled entirely in-house.
Network experts are individually vetted, known individuals—not anonymous contributors. Your NDA covers everyone who works on your project, and you can request the credentials of anyone who contributed to your analysis.
The senior specialists who founded and lead InSilicoNext—setting scientific standards, overseeing quality assurance, and leading the most complex projects personally.
Dr. Ananya Aeron
Founder & Lead Computational BiologistPhD in Computational Genomics, Imperial College London. 12+ years spanning multi-omics pipeline development, cancer genomics, and NGS analysis. Corresponding author on 45+ peer-reviewed publications including Nature Genetics and Genome Research.
Dr. Sofia Reyes
Head of TranscriptomicsPhD in Molecular Biology, University of Barcelona. Specialist in bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics with a focus on tumour microenvironment and immunology. Lead analyst on 900+ transcriptomics projects since 2016.
Dr. James Okonkwo
Head of Genomics & Variant AnalysisPhD in Human Genetics, Wellcome Sanger Institute. Expert in WGS, WES, GWAS, population stratification, and clinical variant interpretation. Previously part of the 100,000 Genomes Project analysis team.
Dr. Hassan Al-Farsi
Head of Biostatistics & Machine LearningPhD in Biostatistics, University of Edinburgh. Specialist in statistical modelling for high-dimensional omics data, ML for genomic feature selection, and clinical trial biostatistics. Active reviewer for Bioinformatics and Briefings in Bioinformatics.
PhD-qualified specialists with deep expertise in their specific domain—from structural biology and metagenomics to long-read data, immunogenomics, and AI-driven omics.
Dr. Mei Lin Zhang
Structural Biology & Drug DiscoveryPhD in Structural Bioinformatics, NTU Singapore. Specialises in AlphaFold2/3 structure prediction, molecular docking, MD simulation analysis, and AI-driven drug target identification for oncology and infectious disease.
Dr. Priya Nair
Metagenomics & MicrobiomePhD in Microbial Genomics, ETH Zurich. Expert in 16S amplicon analysis, shotgun metagenomics, microbiome-metabolome integration, and host-microbiome interaction modelling across gut, oral, and skin microbiome programmes.
Dr. Lucas Fernandez
Single-Cell & EpigenomicsPhD in Developmental Biology, University of Heidelberg. Specialist in scRNA-seq, scATAC-seq, multiome analysis, and chromatin accessibility profiling. Particular expertise in cell trajectory inference and developmental cell atlas construction.
Dr. Amara Diallo
Clinical Bioinformatics & ProteomicsPhD in Systems Biology, Karolinska Institute. Expert in LC-MS/MS proteomics, phosphoproteomics, clinical genomics variant reporting, and biomarker validation for diagnostic applications. Extensive experience supporting clinical trial genomics programmes.
Dr. Yuki Tanaka
Epigenomics & DNA MethylationPhD in Epigenomics, University of Tokyo. Specialist in ChIP-seq, ATAC-seq, RRBS, whole-genome bisulfite sequencing, and chromatin remodelling analysis. Experienced in integrating epigenetic data with transcriptomic and genetic datasets for cancer and ageing research.
Dr. Ravi Kumar
Phylogenomics & Comparative GenomicsPhD in Evolutionary Genomics, Indian Institute of Science, Bangalore. Expert in phylogenetic tree construction, ancestral sequence reconstruction, comparative genome analysis, and molecular clock dating using IQ-TREE, BEAST, and RAxML.
Dr. Elena Vassileva
Proteomics & Mass SpectrometryPhD in Biochemistry, Max Planck Institute of Biochemistry, Munich. Specialises in DIA and DDA proteomics workflows, post-translational modification analysis, protein-protein interaction networks, and cross-linking mass spectrometry for structural proteomics.
Dr. Omar Al-Hassan
AI & Deep Learning for OmicsPhD in Computational Biology, KAUST, Saudi Arabia. Expert in genomic foundation model fine-tuning, transformer architectures for sequence analysis, CNN-based variant calling, and deep learning approaches for multi-omics data integration and phenotype prediction.
Dr. Fatima Malik
Precision Medicine & PharmacogenomicsPhD in Clinical Genomics, Indian Institute of Technology, India. Specialises in pharmacogenomics, drug-gene interaction analysis, polygenic risk score development, and clinical decision support genomics for precision medicine programme implementation.
Dr. Carlos Mendez
Long-Read Sequencing & Genome AssemblyPhD in Genomics, University of Chile. Expert in Oxford Nanopore and PacBio long-read data processing, de novo genome assembly, structural variant detection, isoform characterisation, and telomere-to-telomere assembly workflows for complex genomes.
Dr. Aisha Osei
Cancer Bioinformatics & Liquid BiopsyPhD in Cancer Genomics, University of Cape Town. Specialist in somatic mutation profiling, tumour mutational burden, copy number alteration analysis, ctDNA and cfDNA liquid biopsy, and clonal evolution and tumour heterogeneity modelling.
Dr. Thomas Bergmann
Metabolomics & Systems BiologyPhD in Systems Biology, University of Zurich. Expert in untargeted LC-MS and GC-MS metabolomics, lipidomics, KEGG pathway modelling, flux balance analysis, and multi-omics metabolome integration for cardiovascular disease, diabetes, and ageing research.
Dr. Neha Sharma
Immunogenomics & Immune RepertoirePhD in Immunology, All India Institute of Medical Sciences, New Delhi. Specialist in TCR and BCR repertoire analysis, HLA typing and haplotype calling, immune cell deconvolution, neoantigen prediction, and tumour-immune microenvironment profiling.
Dr. Jae-Won Kim
Spatial Transcriptomics & Multi-omicsPhD in Genomic Medicine, Seoul National University. Expert in Visium, Xenium, MERFISH, and Slide-seq spatial transcriptomics workflows, spatial deconvolution, cell-cell communication analysis, and spatially resolved multi-omics integration for tissue microenvironment mapping.
Beyond our core in-house team, a curated network of domain specialists—researchers, experienced academics, and industry experts—contribute to projects requiring highly specialised knowledge. Every one is individually vetted, holds doctoral or equivalent research credentials, and has an active peer-reviewed publication record.
Every network expert holds a doctoral degree or equivalent qualification in a directly relevant discipline—the same standard applied to our core in-house team.
Expert contributions are always coordinated and reviewed by a core team lead. You communicate with your core in-house contact—never directly with network contributors.
Your confidentiality agreement extends to all contributors on your project. No one outside that agreement ever has access to your data, results, or unpublished findings.
A clear structure that keeps accountability at every step—whether the work is handled entirely in-house or with expert-network contribution.
Your project brief is reviewed by the leadership team, who identify the right core team lead and whether any expert-network contribution is needed. You are told who will work on your project—and their credentials—before work begins.
You always communicate with a core in-house team member, never through a ticket system and never directly with a network contributor. Your core team lead is your single point of contact from scoping to publication.
Before results leave InSilicoNext, a second core team member independently reviews all code, parameter choices, and interpretations. This applies equally to in-house work and work involving expert-network contributions.
Your core team lead remains your contact through peer review, revision, and resubmission—so revision requests are handled by the same people who know your data and analytical decisions.
Tell us your data type, organism, and research question. Our leadership team will confirm whether the work is handled by the core in-house team or with expert-network contribution—and who will be working on it—before you commit.
No commitment required · Response within 24 hours · NDA signed before any data is shared